This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Healthcare Technology Innovators to Invest in Before the New Year
by Urmimala Biswas
Here, we have presented four healthcare technology stocks for stable portfolio gains in 2025: VCYT, OMCL, MASI and ABT.
ARAY Stock Falls Despite Positive Data of CyberKnife in Treating BSM
by Zacks Equity Research
Accuray announces positive study data for its CyberKnife System in treating brainstem metastases.
Reasons to Retain ABT Stock in Your Portfolio Now
by Zacks Equity Research
Investors feel optimistic about Abbott's robust strength in the EPD and Nutrition businesses. Yet, unfavorable forex impacts are concerning.
BSX Trades Near 52-Week High: Does the Stock Hold More Potential?
by Urmimala Biswas
We believe Boston Scientific is one of those MedTech manufacturers that can be considered as the biggest gainers from the Fed's two successive interest rate cuts in 2024.
ABT Stock Up on First Successful LBBAP Procedures With AVEIR Pacemaker
by Zacks Equity Research
Abbott completes the world's first leadless pacing procedures in the left bundle branch of the heart.
Reasons to Retain GE HealthCare Stock in Your Portfolio Now
by Zacks Equity Research
GEHC's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
Reasons to Add McKesson Stock to Your Portfolio Right Now
by Zacks Equity Research
MCK's strategic collaborations and strength in Biologics raise optimism about the stock.
Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $113.29, marking a +0.59% move from the previous day.
Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Astria Therapeutics, Inc. (ATXS) and Abbott (ABT) have performed compared to their sector so far this year.
Leadership in Dialysis Services and Products Drives FMS Stock
by Zacks Equity Research
Fresenius Medical Care leads global dialysis services, driving growth through innovation, restructuring and a strong global footprint in 120+ countries.
Here's Why You Should Retain Stryker Stock in Your Portfolio for Now
by Zacks Equity Research
SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
TransMedics Stock Plunges 57.5% in Three Months: What's Next?
by Debanjana Dey
TMDX is enhancing its current focus on making meaningful progress across each of its growth initiatives. However, macro challenges are likely to hurt its performance.
PBH or ABT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. ABT: Which Stock Is the Better Value Option?
Abbott (ABT) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the closing of the recent trading day, Abbott (ABT) stood at $114.14, denoting a -1.18% change from the preceding trading day.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Is Invesco Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV
Abbott (ABT) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $115.59, marking a -0.33% move from the previous day.
Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Abbott (ABT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
by Zacks Equity Research
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott (ABT) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Abbott (ABT) stood at $118.77, denoting a -0.15% change from the preceding trading day.
Growing EPD Business Supports ABT Stock Amid Macroeconomic Issues
by Zacks Equity Research
Abbott has a unique opportunity to scale a capital-efficient licensing model that can help the emerging market population access life-changing medicines.
The Zacks Analyst Blog Abbott, BlackRock, ConocoPhillips, NetSol and Optex Systems
by Zacks Equity Research
Abbott, BlackRock, ConocoPhillips, NetSol and Optex Systems are included in this Analyst Blog.
Top Research Reports for Abbott, BlackRock & ConocoPhillips
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), BlackRock, Inc. (BLK) and ConocoPhillips (COP), as well as two micro-cap stocks, NetSol Technologies, Inc. (NTWK) and Optex Systems Holdings, Inc (OPXS).
ABT Stock Benefits From First Patient Procedures With TAVI System
by Zacks Equity Research
Abbott announces its investigational TAVI balloon-expandable system???s first patient procedures. This investigational TAVI system aims to offer best-in-class heart blood flow.